본문 바로가기
bar_progress

Text Size

Close

Naibec Launches Full-Scale CDMO Business for Peptide Pharmaceuticals

NaiVec is expanding its business area to peptide pharmaceutical CDMO (Contract Development and Manufacturing Organization).


On the 22nd, NaiVec announced that it is entering the peptide active pharmaceutical ingredient CDMO business based on its proprietary technology.


A company representative explained, "The business expansion started when global pharmaceutical companies requested NaiVec to produce peptide pharmaceuticals," adding, "There are only a handful of CDMO companies capable of producing peptide-based pharmaceuticals at the level desired by global pharmaceutical companies."


They continued, "Due to supplier restrictions and high technical difficulty, the average selling price (ASP) is also high," and added, "NaiVec has the potential for sales growth beyond its existing business."


Unlike CMO (Contract Manufacturing Organization), which only handles pharmaceutical production, CDMO is involved from the drug development stage, requiring design capabilities. NaiVec has experience in independently manufacturing peptide-based drug delivery systems and possesses the capability to develop production processes for ‘peptide pharmaceuticals.’ It is also recognized externally for its strong competitiveness in the CDMO business.


Peptide pharmaceuticals are widely used in immune-related diseases such as booster vaccines in the form of raw materials, active pharmaceutical ingredients, and excipients. Interest in peptides has increased as one of the essential components of vaccines due to the rise in vaccine production demand following the COVID-19 pandemic.


A NaiVec representative stated, "The peptide active pharmaceutical ingredient CDMO business was decided to enter the market after being proposed by pharmaceutical companies," and added, "Based on peptide production facilities, quality control facilities, and GMP (Good Manufacturing Practice) certification, we are currently in discussions for CDMO contracts with various global pharmaceutical companies."


© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Special Coverage


Join us on social!

Top